Expression of the co-signaling molecules CD40-CD40L and their growth inhibitory effect on pancreatic cancer in vitro

He, Songbing; Zhao, Hua; Fei, Min; Wu, Yugang; Wang, Liang; Zhu, Xiaoli; Li, Dechun

doi:10.3892/or.2012.1790

Cited by 18 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, CD40 is also expressed on various malignancies [136]. On many of these malignant cells, the cross-linking of CD40 triggers apoptotic cell death or inhibits proliferation, as for instance, seen upon CD40L treatment of primary ascites-derived ovarian carcinoma cells [137].…”

Section: Cd40l Biologymentioning

confidence: 99%

Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy

Bremer

2013

ISRN Oncology

View full text Add to dashboard Cite

The tumor necrosis factor (TNF) ligand and cognate TNF receptor superfamilies constitute an important regulatory axis that is pivotal for immune homeostasis and correct execution of immune responses. TNF ligands and receptors are involved in diverse biological processes ranging from the selective induction of cell death in potentially dangerous and superfluous cells to providing costimulatory signals that help mount an effective immune response. This diverse and important regulatory role in immunity has sparked great interest in the development of TNFL/TNFR-targeted cancer immunotherapeutics. In this review, I will discuss the biology of the most prominent proapoptotic and co-stimulatory TNF ligands and review their current status in cancer immunotherapy.

show abstract

Section: Cd40l Biologymentioning

confidence: 99%

Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy

Bremer

2013

ISRN Oncology

View full text Add to dashboard Cite

show abstract

“…This effect is absolutely dependent on CD8 + T-cells and independent of CD4 + T-cells. 22 , 23 , 24 These analyses indicate that immune activation and direct tumor cytotoxicity after systemic CD40 activation can have synergistic antitumor effects.…”

Section: Discussionmentioning

confidence: 91%

Soluble CD40 in plasma and malignant pleural effusion with non‐small cell lung cancer: A potential marker of prognosis

Qin

et al. 2015

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

ObjectiveSoluble CD40 (sCD40) is a potential modulator for both antitumor responses and CD40-based immunotherapy; however the levels and significance of sCD40 in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion are unknown.MethodsForty-eight patients with lung cancer were treated in our institutions from January 2008 to January 2010. Peripheral blood and pleural effusion samples were collected from each subject. sCD40 levels in plasma and malignant pleural effusions supernatant were measured. The CD40L expression on CD3t T-cells was confirmed by flow cytometric direct immunofluorescence analysis. All patients were followed up after the study ended on January 1, 2010.ResultsPatients with malignant pleural effusion of NSCLC had elevated circulating and pleural effusion levels of sCD40, and these elevated sCD40 levels were associated with advanced diseases and a poor prognosis.ConclusionsThese findings indicate that elevated sCD40 may have a role in modulating antitumor responses and may also be a useful prognostic marker.

show abstract

“…Furthermore, increased expression of inhibitory molecules on inactivated T-cells has been suggested as another way to induce pancreatic cancer immunosuppression. Thus, pancreatic tumors show a high expression of CD40, a cell membrane receptor of the tumor necrosis factor family that modulates immune response, and this overexpression is associated to higher TNM staging and metastasis [41].…”

Section: Pda Tumor Heterogeneity and Immune Responsesmentioning

confidence: 99%

Immune Evasion in Pancreatic Cancer: from Mechanisms to Therapy<strong> </strong>

Martínez-Bosch¹,

Vinaixa²,

Navarro³

2017

Preprint

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDA), the most frequent type of pancreatic cancer, is one of the main unfinished businesses in the biomedical and clinical fields, with still discouraging 5 year survival rates and poor therapy efficiency. PDA abundant desmoplasia has for long played the lead in the mechanisms involved in poor drug performance, being the main source of cytokines and chemokines orchestrating rapid and silent tumor progression and guilty of isolating tumor cells into a extense fibrotic reaction resulting in inefficient drug delivery. However, since immunotherapy was proclaimed the breakthrough of the year back to 2013, the focus in the stroma of pancreatic cancer has interestingly moved from activated fibroblasts to the immune compartment, trying to understand the immunosuppressive factors that play part in the strong immune evasion that characterizes PDA. PDA microenvironment is highly immune-suppressive, being basically composed of T regulatory cells (Tregs), tumor-associated macrophages (TAMs) and myeloid-derived suppressive cells (MDSCs), which boycott CD8+ T-cell duties in tumor recognition and clearance. Interestingly, preclinical data have highlighted the importance of this immune evasion as the source of resistance to single checkpoint immunotherapies and cancer vaccines and point at pathways inhibiting the immune attack as the key to solve the therapy puzzle. Here, we will discuss the molecular mechanisms involved in PDA immune escape as well as the state of the art of the PDA immunotherapy.

show abstract

Expression of the co-signaling molecules CD40-CD40L and their growth inhibitory effect on pancreatic cancer in vitro

Cited by 18 publications

References 30 publications

Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy

Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy

Soluble CD40 in plasma and malignant pleural effusion with non‐small cell lung cancer: A potential marker of prognosis

Immune Evasion in Pancreatic Cancer: from Mechanisms to Therapy<strong> </strong>

Contact Info

Product

Resources

About